Aardvark Therapeutics, Inc. Overview
Pro stress-test →Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting bitter taste receptors to treat metabolic diseases, particularly hyperphagia and obesity. The company's lead program, ARD-101, was in Phase 3 trials for Prader-Willi Syndrome until March 2026 when the company voluntarily paused the HERO trial due to cardiac safety signals detected in healthy volunteer studies.
Strategic Profile
Pro stress-test →Aardvark focuses on novel mechanisms that activate homeostatic pathways to suppress hunger, addressing large unmet medical needs in rare and acquired forms of pathological eating disorders. The company's approach targets biological pathways distinct from traditional GLP-1 therapeutics, positioning it as a potential differentiated competitor in the metabolic disease treatment space.
Competitive Landscape
Pro stress-test →Aardvark competes indirectly with large pharma GLP-1 providers (Novo Nordisk, Eli Lilly) in metabolic disease treatment, but addresses distinct rare disease niches. Direct clinical-stage competitors in hunger-suppression include emerging biotech firms developing similar bitter taste receptor or homeostatic pathway modulators. Aardvark's differentiation lies in its non-GLP-1 mechanism targeting gut-restricted bitter taste receptors.
Industry Context
Aardvark Therapeutics, Inc. operates in Biopharmaceutical - Clinical Stage, Metabolic Diseases & Rare Genetic Disorders.
Key facts
Founded: 2017 · Headquarters: San Diego, California · Market cap: $272M